Lyell Immunopharma, Inc. (LYEL)
12.26
-0.62
(-4.81%)
USD |
NASDAQ |
Sep 10, 15:23
Lyell Immunopharma Shareholders Equity (Quarterly) : 233.82M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 233.82M |
| March 31, 2026 | 273.66M |
| December 31, 2025 | 248.20M |
| September 30, 2025 | 329.12M |
| June 30, 2025 | 298.92M |
| March 31, 2025 | 336.52M |
| December 31, 2024 | 382.82M |
| September 30, 2024 | 530.70M |
| June 30, 2024 | 566.50M |
| March 31, 2024 | 603.16M |
| December 31, 2023 | 654.95M |
| September 30, 2023 | 697.57M |
| Date | Value |
|---|---|
| June 30, 2023 | 736.86M |
| March 31, 2023 | 783.83M |
| December 31, 2022 | 833.25M |
| September 30, 2022 | 820.03M |
| June 30, 2022 | 868.04M |
| March 31, 2022 | 881.25M |
| December 31, 2021 | 929.79M |
| September 30, 2021 | 986.47M |
| June 30, 2021 | 1.022B |
| March 31, 2021 | -334.05M |
| December 31, 2020 | -292.53M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 311.15M |
| Total Liabilities (Quarterly) | 77.34M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 5.356 |
| Net Debt Paydown Yield | 0.64% |